Germline BRCA test → adjuvant PARP inhibitor
A blood test for inherited BRCA mutations unlocks a year of olaparib after surgery, which improves survival.
OlympiA: iDFS HR 0.58, OS HR 0.72. Requires germline testing of every TNBC and high-risk HER2-negative breast cancer patient at diagnosis.
Pages like this
not linked directly; found by shared links- TrialPOLO
Shares PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- PersonJennifer K. Litton
Shares PARP inhibitors, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
- TermGermline BRCA mutation (gBRCA)
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonAndrew Tutt
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- PersonAlan Ashworth
Shares PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonJudy E. Garber
Shares OlympiA, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
- PersonSusan M. Domchek
Shares Olaparib, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).